Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.05
(
-1.02%
)
Bitcoin
76,422.14
(
0.12%
)
News Focus
News Focus
Post# of 57798
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

gfp927z

Send PM Follow Ignore
Followers 97
Posts 38776
Boards Moderated 89
Alias Born 03/22/2005

gfp927z

Re: neuroinv post# 37829

Wednesday, 10/26/2011 2:31:33 PM

Wednesday, October 26, 2011 2:31:33 PM

Post# of 57798
Neuro, >>> two different companies developing a compound for two different indications <<<


But that's the situation we have here -- Samyang advancing CX-1739 for a Neurodegeneration indication, and then Cortex licensing CX-1739 to a different partner for SA/RD or ADHD. Having split ownership of the same compound between two pharmas for different indications seems like something prospective pharma partners would want to avoid.



























Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today